Stem Pharm, which provides advanced biomaterials for cell and tissue manufacturing, is part of the 10th cycle for the Illumina Accelerator, which began this month in San Francisco.

Per the requirements of the program, Stem Pharm must have at least two co-founders in the Bay Area for the duration of the six months. Each of the five companies will focus on technology advancement and pitch development, receive active coaching, meet with VCs and complete all experiments.

“With every cycle, we’ve seen another level of excellence in both the ideas and the ambition of these startups,” Co-Founder and Global Head of Illumina Accelerator Amanda Cashin said in a statement.

According to a release, Illumina Accelerator is the first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. Since its founding in 2014, it has helped 33 company graduates raise more than $300 million in collective funding.